Examining the CONVOKE Clinical Trial
Panelists discuss the CONVOKE clinical trial, a 16-week study focusing on patients with negative symptoms of schizophrenia.
The trial incorporated patient input in app development, showing improvements in negative symptoms, depression, and cognitive function.
The CONVOKE clinical trial represents a significant advancement in developing targeted treatments for patients with negative symptoms of schizophrenia.
Trial Design
The 16-week trial enrolled patients with pure negative symptoms, excluding those with prominent positive symptoms, severe cognitive impairment, suicidality, or substance abuse.
- Patient participation in designing the digital therapeutic application
- Authentic address of lived experiences and symptom presentations
- Non-reliance on clinical literature and technological expertise alone
Author's summary: The CONVOKE trial is a significant advancement in schizophrenia treatment.
More News
- Netherlands faces €5bn loss over international student limits
- Creator Dolly Singh Shines As India’s Instagram 2025 Rings Award Winner!
- Go Fast, Get Nowhere: Here's How Much Speed Kills EV Range
- Supreme Court Seems Inclined to Limit Race-Based Electoral Districts Under the Voting Rights Act - Chapelboro.com
- Matchday Guide | Sunderland vs Wolves
- Jennifer Lopez Claims Brett Goldstein Is the Best Kisser
- Did Qatari Money Drive Trump’s Push for Gaza Ceasefire?
- Armenians in Jerusalem and the dilemma of Israel's recognition of the Armenian Genocide
- What’s the New 2026 Estate Tax Exemption Amount?
- Pokemon Legends: Z-A’s Mega Shards Explained (and What to Use Them for)